UK markets open in 2 hours 23 minutes

Oragenics, Inc. (OGEN)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
1.0600-0.0300 (-2.75%)
At close: 03:53PM EDT
1.1100 +0.05 (+4.72%)
After hours: 06:50PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0900
Open1.1000
Bid0.0000 x 2200
Ask0.0000 x 3000
Day's range1.0490 - 1.1500
52-week range1.0100 - 7.7400
Volume57,378
Avg. volume100,238
Market cap4.75M
Beta (5Y monthly)0.32
PE ratio (TTM)N/A
EPS (TTM)-9.1800
Earnings date10 May 2024 - 14 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

    SARASOTA, Fla., April 19, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April 18, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. Specifically, the letter states that the Company is not in compliance with the conti

  • Business Wire

    Oragenics, Inc. Files 10K and Provides Company Update

    SARASOTA, Fla., April 01, 2024--Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve t

  • Business Wire

    Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

    SARASOTA, Fla., March 18, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James "Jim" Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion. ONP-002 i